Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: Evidence for reduced toxicity and enhanced antitumor activity in mice

Cancer Research

Volumn 59, Issue 11, 1999, Pages 2608-2614

  Gu, Dan Ling ^a   Gonzalez, Ana Maria ^a   Printz, Marie A ^a   Doukas, John ^a   Ying, Wenbin ^a   D'Andrea, Mark ^a   Hoganson, Diana K ^a   Curiel, David T ^b   Douglas, Joanne T ^b   Sosnowski, Barbara A ^a   Baird, Andrew ^a   Aukerman, Sharon Lea ^c   Pierce, Glenn F ^a  

^a Selective Genetics Inc   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; GANCICLOVIR; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CELL GROWTH; GENE DELETION; GENE EXPRESSION REGULATION; GENE TARGETING; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR GENE; SIGNAL TRANSDUCTION; TISSUE SPECIFICITY;

ADENOVIRIDAE; ALANINE TRANSAMINASE; ANIMALS; ANTIVIRAL AGENTS; ASPARTATE AMINOTRANSFERASES; BETA-GALACTOSIDASE; BIOLOGICAL MARKERS; DEFECTIVE VIRUSES; FEMALE; FIBROBLAST GROWTH FACTOR 2; GANCICLOVIR; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOTOXINS; LIVER; MELANOMA, EXPERIMENTAL; MICE; NECROSIS; ORGAN SPECIFICITY; RECEPTORS, VIRUS; RECOMBINANT FUSION PROTEINS; SIMPLEXVIRUS; THYMIDINE KINASE; TRANSFECTION; TRANSGENES; TROPISM;

EID: 0033152218     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Roth, J. A., and Cristiano, R. J. Gene therapy for cancer: what have we done and where are we going? J. Natl. Cancer Inst., 88: 21-39, 1997.
2. Dranoff, G. Cancer gene therapy: connecting basic research with clinical inquiry. J. Clin. Oncol., 16: 2548-2556, 1998.
3. Roth, J. A., Swisher, S. G., Merritt, J. A., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., El-Naggar, A. K., Fossella, F. V., Glisson, B. S., Hong, W. K., Khurl, F. R., Kurie, J. M., Nesbitt, J. C., Pisters, K., Putnam, J. B., Schrump, D. S., Shin, D. M., and Walsh, G. L. Gene therapy for non-small cell lung cancer: a preliminary report of a Phase I trial of adenoviral p53 gene replacement. Semin. Oncol., 25: 33-37, 1998.
4. Sterman, D. H., Treat, J., Litzky, L. A., Amin, K. M., Coonrod, L., Molnar-Kimber, K., Recio, A., Knox, L., Wilson, J. M., Albelda, S. M., and Kaiser, L. R. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a Phase I clinical trial in malignant mesothelioma. Hum. Gene Ther., 9: 1083-1092, 1998.
5. Crystal, R. G., Hirschowitz, E., Lieberman, M., Daly, J., Kazam, E., Henschke, C., Yankelevitz, D., Kemeny, N., Silverstein, R., Ohwada, A., Russi, T., Mastrangeli, A., Sanders, A., Cooke, J., and Harvey, B. G. Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum. Gene Ther., 8: 985-1001, 1997.
6. Rubin, J., Galanis, E., Pilot, H. C., Richardson, R. L., Burch, P. A., Charboneau, J. W., Reading, C. C., Lewis, B. D., Stahl, S., Akporiaye, E. T., and Harris, D. T. Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7. Gene Ther., 4: 419-425, 1997.
7. Wickham, T. J., Tzeng, E., Shears, L. L., II, Roelvink, P. W., Li, Y., Lee, G. M., Brough, D. E., Lizonova, A., and Kovesdi, I. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J. Virol., 71: 8221-8229, 1997.
8. Yang, Y., Nunes, F. A., Berencsi, K., Furth, E. E., Gonczol, E., and Wilson, J. M. Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA, 91: 4407-4411, 1994.
9. Yang, Y., Ertl, H. C. J., and Wilson, J. M. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with El-deleted recombinant adenoviruses. Immunity, I: 433-442, 1994.
10. Gao, G-P., Yang, Y., and Wilson, J. M. Biology of adenovirus vectors with El and E4 deletions for liver-directed gene therapy. J. Virol., 70: 8934-8943, 1996.
11. Morral, N., O'Neal, W., Zhou, H., Langston, C., and Beaudet, A. Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors. Hum. Gene Ther., 8: 1275-1286, 1997.
12. Douglas, J. T., Rogers, B. E., Rosenfeld, M. E., Michael, S. I., Feng, M., and Curiel, D. T. Targeted gene delivery by tropism-modified adenoviral vectors. Nat. Biotechnol., 14: 1574-1578, 1996.
13. Michael, S. I., Hong, J. S., Curiel, D. T., and Engler, J. A. Addition of a short peptide ligand to the adenovirus fiber protein. Gene Ther., 2: 660-668, 1995.
14. Wickham, T. J., Lee, G. M., Titus, J. A., Sconocchia, G., Bakacs, T., Kovesdi, I., and Segal, D. M. Targeted adenovirus-mediated gene delivery to T cells via CD3. J. Virol., 71: 7663-7669, 1997.
15. Wickham, T. J., Segal, D. M., Roelvink, P. W., Carrion, M. E., Lizonova, A., Lee, G. M., and Kovesdi, I. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J. Virol., 70: 6831-6838, 1996.
16. Wickham, T. J., Roelvink, P. W., Brough, D. E., and Kovesdi. I. Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat. Biotechnol., 14: 1570-1573, 1996.
17. Watkins, S. J., Mesyanzhinov, V. V., Kurochkina, L. P., and Hawkins, R. E. The 'adenobody' approach to viral targeting: specific and enhanced adenoviral gene delivery. Gene Ther., 4: 1004-1012, 1997.
18. Rogers, B. E., Douglas, J. T., Sosnowski, B. A., Ying, W., Pierce, G. F., Buchsbaum, D. J., Della Manna, D., Baird, A., and Curiel, D. T. Enhanced in vivo gene delivery to human ovarian cancer xenografts utilizing a tropism-modified adenovirus vector. Tumor Targeting, 3: 25-31, 1998.
19. Worgall, S., Wolff, G., Falck-Pedersen, E., and Crystal, R. G. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum. Gene Ther., 8: 37-44, 1997.
20. Kuzmin, A. I., Finegold, M. J., and Eisensmith, R. C. Macrophage depletion increases the safety, efficacy and persistence of adenovirus-mediated gene transfer in vivo. Gene Ther, 4: 309-316, 1997.
21. Tomko, R. P., Xu, R., and Philipson, L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B Coxsackieviruses. Proc. Natl. Acad. Sci. USA, 94: 3352-3356, 1997.
22. Goldman, C. K., Rogers, B. E., Douglas, J. T., Sosnowski, B. A., Ying, W., Siegal, G. P., Baird, A., Campain, J. A., and Curiel, D. T. Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Res., 57: 1447-1451, 1997.
23. Doukas, J., Hoganson, D. K., Ong, M., Ying, W., Lacey, D. L., Baird, A., Pierce, G. F., and Sosnowski, B. A. Retargeted delivery of adenoviral vectors through fibroblast growth factor receptors involves unique cellular pathways. FASEB, in press, 1999.
24. Kobrin, M. S., Yamanaka, Y., Friess, H., Lopez, M. E., and Korc, M. Aberrant expression of type 1 fibroblast growth factor receptor in human pancreatic adenocarcinomas. Cancer Res., 53: 4741-4744, 1993.
25. Jaakkola, S., Salmikangas, P., Nylund, S., Partanen, J., Armstrong, E., Pyrhönen, S., Lehtovirta, P., and Nevanlinna, H. Amplification of fgfr4 gene in human breast and gynecological cancers. Int. J. Cancer, 54: 378-382, 1993.
26. Dib, A., Adélaïde, J., Chaffanet, M., Imbert, A., Le Paslier, D., Jacquemier, J., Gaudray, P., Theillet, C, Birnbaum, D., and Pébusque, M-J. Characterization of the region of the short arm of chromosome 8 amplified in breast carcinoma. Oncogene, 10: 995-1001, 1995.
27. Morrison, R. S., Yamaguchi, F., Saya, H., Bruner, J. M., Yahanda. A. M., Donehower, L. A., and Berger, M. Basic fibroblast growth factor and fibroblast growth factor receptor I are implicated in the growth of human astrocytomas. J. Neuro-oncol., 18: 207-216, 1994.
28. Xerri, L., Battyani, Z., Grob, J-J., Parc, P., Hassoun, J., Bonerandi, J-J., and Birnbaum, D. Expression of FGF1 and FGFR1 in human melanoma tissues. Melanoma Res., 6: 223-230, 1996.
29. Chandler, L. A., Sosnowski, B. A., Greenlees, L., Aukerman, S. L., Baird, A., and Pierce, G. F. Prevalent expression of fibroblast growth factor (FGF) receptors and FGF2 in human tumor cell lines. Int. J. Cancer, 81: 451-458, 1999.
30. Ornitz, D. M., Xu, J., Colvin, J. S., McEwen, D. G., MacArthur, C. A., Coulier, F., Gao, G., and Goldfarb, M. Receptor specificity of the fibroblast growth factor family. J. Biol. Chem., 271: 15292-15297, 1996.
31. Sosnowski, B. A., Gonzalez, A. M., Chandler, L. A., Buechler, Y. J., Pierce, G. F., and Baird, A. Targeting DNA to cells with basic fibroblast growth factor (FGF2). J. Biol. Chem., 271: 33647-33653, 1996.
32. Rancourt, C., Rogers, B. E., Sosnowski, B. A., Wang, M., Piche, A., Pierce, G. F., Alvarez, R. D., Siegal, G. P., Douglas, J. T., and Curiel, D. T. Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. Clin. Cancer Res., 4: 2455-2461, 1998.
33. Graham, F., and Prevec, L. Manipulation of adenovirus vectors. In: E. J. Murray and J. M. Walker (eds.), Methods in Molecular Biology, Vol. 7, pp. 109-128. Clifton, NJ: Humana Press, 1991.
34. Oswald, H., Heinemann, F., Nikol, S., Salmons, B., and Günzburg, W. H. Removal of an inhibitor of marker enzyme activity in artery extracts by chelating agents. Biotechniques, 22: 78-81, 1997.
35. Hu, Z., Evarts, R. P., Fujio, K., Marsden, E. R., and Thorgeirsson, S. S. Expression of fibroblast growth factor receptors flg and bek during hepatic ontogenesis and regeneration in the rat. Cell Growth Differ., 6: 1019-1025, 1995.
36. Wagner, E., Zatloukal, K., Cotten, M., Kirlappos, H., Mechtler, K., Curiel, D. T., and Birnstiel, M. L. Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes. Proc. Natl. Acad. Sci. USA, 89: 6099-6103, 1992.
37. Lindner, V., Lappi, D. A., Baird, A., Majack, R. A., and Reidy, M. A. Role of basic fibroblast growth factor in vascular lesion formation. Circ. Res., 68: 106-113, 1991.
38. Whalen, G. F., Shing, Y., and Folkman, J. The fate of intravenously administered bFGF and the effect of heparin. Growth Factors, 1: 157-164, 1989.
39. Edelman, E. R., Nugent, M. A., and Kamovsky, M. J. Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition. Proc. Natl. Acad. Sci. USA, 90: 1513-1517, 1993.
40. Mazue, G., Newman, A. J., Scampini, G., Della Torre, P., Hard, G. C., Iatropolous, I., Williams, G. M., and Bagnasco, S. M. The histopathology of kidney changes in rats and monkeys following intravenous administration of massive doses of FCE 26184, human basic fibroblast growth factor. Toxicol. Pathol., 21: 490-501, 1993.
41. Yan, G., Fukabori, Y., McBride, G., Nikolaropolous, S., and McKeehan, W. L. Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol. Cell. Biol., 13: 4513-4522, 1993.
42. Wang, Y., and Becker, D. Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat. Med., 3: 887-893, 1997.
43. Casscells, W., Lappi, D. A., Olwin, B. B., Wai, C., Siegman, M., Speir, E. H., Sasse, J., and Baird, A. Elimination of smooth muscle cells in experimental restenosis: targeting of fibroblast growth factor receptors. Proc. Natl. Acad. Sci. USA, 89: 7159-7163, 1992.
44. Endoh, M., Pulsinelli, W. A., and Wagner, J. A. Transient global ischemia induces dynamic changes in the expression of bFGF and the FGF receptor. Mol. Brain Res., 22: 76-88, 1994.
45. Marchese, C., Chedid, M., Dirsch, O. R., Csaky, K. G., Santanelli, F., Latini, C., LaRochelle, W. J., Torrisi, M. R., and Aaronson, S. A. Modulation of keratinocyte growth factor and its receptor in reepithelializing human skin. J. Exp. Med., 182: 1369-1376, 1995.
46. Werner, S., Peters, K. G, Longaker, M. T., Fuller-Pace, F., Banda, M. J., and Williams, L. T. Large induction of keratinocyte growth factor expression in the dermis during wound healing. Proc. Natl. Acad. Sci. USA, 89: 6896-6900, 1992.